Astellas, Takeda, Lilly-Innovent and more—FiercePharmaAsia by Angus Liu Friday, January 17, 2020 Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.
Shire surprises Takeda with €398M tax bill on AbbVie breakup fee by Angus Liu Monday, January 13, 2020 The additional tax charge is related to the $1.64 billion breakup fee AbbVie paid Shire in its nixed $55 billion takeover bid five years ago.
AZ-Daiichi, Astellas, Prevnar rival and more—FiercePharmaAsia by Angus Liu Friday, January 3, 2020 Daiichi and AZ's Enhertu as well as and Astellas and Seattle Genetics' Padcev won FDA nods as China approved rivals to Prevnar and Gardasil.
10. Novartis/Takeda's Xiidra by Angus Liu Selling Shire’s legacy dry eye drug Xiidra to Novartis is one of several divestitures Takeda inked in 2019 to pare down the huge debt load incurred in its $59 billion takeover of the rare disease giant.
Drugmakers' oncology, rare diseases rebrands may stay in 2020 by Kyle Blankenship Thursday, December 19, 2019 Lately, pharmas have been rebranding—more often than not, around oncology, rare diseases or both—and more could join the fold in 2020.
AZ-Daiichi, J&J-Legend, Samsung and more—FiercePharmaAsia by Angus Liu Friday, December 13, 2019 AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung execs.
Takeda details Ninlaro's miss in AL amyloidosis by Carly Helfand Monday, December 9, 2019 Back in June, Takeda scrapped a Ninlaro trial in rare disease light-chain (AL) amyloidosis. Saturday, it shared the data behind the decision.
Astellas, China's NRDL, Hanmi and more—FiercePharmaAsia by Angus Liu Friday, December 6, 2019 Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.
Takeda's dengue vaccine efficacy slips after 12-month review by Eric Sagonowsky Monday, November 25, 2019 In a new 18-month analysis, Takeda's dengue vaccine efficacy slipped to 73.3%, down from 80% in an earlier analysis.
Takeda eyes Alunbrig earlier use with Xalkori head-to-head data by Angus Liu Friday, November 22, 2019 After a longer follow-up of 25 months, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC.
